HardEndocrinologyObesity and CVD risk pharmacotherapyau-amcau-racp
A 36-year-old woman with BMI 38 kg/m² and well-controlled hypertension asks about pharmacological options for weight loss and cardiovascular risk reduction. She has no diabetes but a strong family history of myocardial infarction. Recent data show she qualifies for a GLP-1 receptor agonist approved for weight management and CVD risk reduction in people with obesity and established or high CVD risk. Which agent matches this description in current Australian practice?